OpenOnco · Treatment Plan

Treatment plan — Colorectal carcinoma

PLAN-CRC-MET-RAS-WT-LEFT-1L-001-V1 · v1 · 2026-05-12

Patient

CRC-MET-RAS-WT-LEFT-1L-001 · Algorithm: ALGO-CRC-METASTATIC-1L

DiagnosisColorectal carcinoma

MOH / ICD-10C18-C20

ICD-O-38140/3; C18, C19, C20

StageIV

Histologyadenocarcinoma

Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks

✅ Covered biomarkers (matched in KB)

Biomarker	Variant	ESCAT	Evidence	Clinical significance	Drugs	Sources
No clinically actionable variants matched in this profile.

⚠️ Not included in plan

Biomarker	Status
BIO-MSI-STATUS	BIO definition in KB; no ESCAT BMA entry — verify with clinician
BIO-BRAF-V600E	Excluded (negative)
KRAS	Not in KB — ask clinician to verify
NRAS	Not in KB — ask clinician to verify

Primary current-line option

Standard plan

★ DEFAULT

Indication

IND-CRC-METASTATIC-1L-RAS-WT-LEFT

Regimen

FOLFOX + Cetuximab

Drugs + NSZU

Oxaliplatin (DRUG-OXALIPLATIN) 85 mg/m² · IV day 1 · IV ✓ NSZU covered
Leucovorin (DRUG-LEUCOVORIN) 400 mg/m² · IV day 1 · IV ✓ NSZU covered
5-Fluorouracil (DRUG-5-FLUOROURACIL) 400 mg/m² IV bolus + 2400 mg/m² CIV over 46h · Day 1 bolus, day 1-2 CIV · IV ✓ NSZU covered
Cetuximab (DRUG-CETUXIMAB) 500 mg/m² q2w (preferred for FOLFOX schedule; alternatively 400 mg/m² loading then 250 mg/m² weekly) · IV day 1 of each 14-d cycle · IV ✓ NSZU covered

Reason

Primary current-line option selected by ALGO-CRC-METASTATIC-1L at step 2; branch-driving red flag: RF-CRC-RAS-WT.

Other current-line alternatives (4 tracks)

Same treatment line; review when biomarker, access, contraindication, or patient-context assumptions change.

Aggressive plan

Indication

IND-CRC-OLIGOMET-LIVER-LIMITED

Regimen

FOLFOX (mFOLFOX6)

Drugs + NSZU

Oxaliplatin (DRUG-OXALIPLATIN) 85 mg/m² · IV over 2h, day 1 · IV ✓ NSZU covered
Leucovorin (DRUG-LEUCOVORIN) 400 mg/m² · IV over 2h, day 1 (concurrent with oxaliplatin) · IV ✓ NSZU covered
5-Fluorouracil (DRUG-5-FLUOROURACIL) 400 mg/m² IV bolus + 2400 mg/m² CIV over 46h · Day 1 bolus, day 1-2 CIV · IV ✓ NSZU covered

Reason

Current-line alternative presented for HCP consideration

Aggressive plan

Indication

IND-CRC-METASTATIC-1L-MSI-H-PEMBRO

Regimen

Pembrolizumab monotherapy (MSI-H mCRC 1L)

Drugs + NSZU

Pembrolizumab (DRUG-PEMBROLIZUMAB) 200 mg IV q3w OR 400 mg IV q6w · Until progression / unacceptable toxicity / 35 cycles (about 2 years) · IV ⚠ NSZU — not for this indication

Hard contraindications

CI-PEMBROLIZUMAB-AUTOIMMUNE

Reason

Current-line alternative presented for HCP consideration

Aggressive plan

Indication

IND-CRC-METASTATIC-1L-FOLFOXIRI-BEV

Regimen

FOLFOXIRI + Bevacizumab

Drugs + NSZU

Irinotecan (DRUG-IRINOTECAN) 165 mg/m² · IV over 1h, day 1 · IV ✓ NSZU covered
Oxaliplatin (DRUG-OXALIPLATIN) 85 mg/m² · IV over 2h, day 1 · IV ✓ NSZU covered
Leucovorin (DRUG-LEUCOVORIN) 200 mg/m² · IV over 2h, day 1 · IV ✓ NSZU covered
5-Fluorouracil (DRUG-5-FLUOROURACIL) 3200 mg/m² CIV over 48h · Day 1-2 (no bolus) · IV ✓ NSZU covered
Bevacizumab (DRUG-BEVACIZUMAB) 5 mg/kg · IV day 1, before chemotherapy · IV ✓ NSZU covered

Reason

Current-line alternative presented for HCP consideration

Aggressive plan

Indication

IND-CRC-METASTATIC-1L-FOLFOX-BEV

Regimen

FOLFOX + Bevacizumab

Drugs + NSZU

Oxaliplatin (DRUG-OXALIPLATIN) 85 mg/m² · IV day 1 · IV ✓ NSZU covered
Leucovorin (DRUG-LEUCOVORIN) 400 mg/m² · IV day 1 · IV ✓ NSZU covered
5-Fluorouracil (DRUG-5-FLUOROURACIL) 400 mg/m² IV bolus + 2400 mg/m² CIV over 46h · Day 1 bolus, day 1-2 CIV · IV ✓ NSZU covered
Bevacizumab (DRUG-BEVACIZUMAB) 5 mg/kg · IV day 1 · IV ✓ NSZU covered

Reason

Current-line alternative presented for HCP consideration

Why this branch was chosen

Triggers from the patient profile that fired and drove the chosen branch.

Step 2 → branch IND-CRC-METASTATIC-1L-RAS-WT-LEFT

RF-CRC-RAS-WT ★ winner: Metastatic colorectal cancer with RAS wild-type status: KRAS exon 2 (codons 12, 13), exon 3 (codons 59, 61), exon 4 (codons 117, 146) AND NRAS exon 2/3/4 ALL wild-type by NGS or extended-RAS PCR. Defines the ~50% of mCRC eligible for anti-EGFR monoclonal antibody therapy (cetuximab, panitumumab) when combined with chemotherapy backbone. Left-sided RAS-WT mCRC particularly benefits from 1L anti-EGFR + FOLFOX/ FOLFIRI (CALGB/SWOG-80405, FIRE-3, PRIME, CRYSTAL — survival benefit driven by left-sided primaries; right-sided RAS-WT does NOT benefit and routes to bevacizumab + chemo). SRC-NCCN-COLON-2025SRC-ESMO-COLON-2024

Pre-treatment investigations

Investigations before treatment start · critical / standard / desired · merged across tracks

ID	Name	Priority	Category	Where to order	Needed for
TEST-CT-CHEST-ABDOMEN-PELVIS	CT chest + abdomen + pelvis with IV contrast	Critical	imaging	—	aggressive
TEST-DMMR-IHC	MMR proteins IHC (MLH1 / MSH2 / MSH6 / PMS2)	Critical	histology	CSD Lab ✓ (code TBC)	aggressive
TEST-MSI-PCR-OR-NGS	MSI status by PCR or NGS	Critical	histology	CSD Lab: M065 CSD Lab ✓ (code TBC)	aggressive
TEST-RAS-EXTENDED	RAS extended panel (KRAS exons 2-4 + NRAS exons 2-4)	Critical	histology	CSD Lab: M065	aggressive
TEST-CEA	CEA	Standard	lab	—	aggressive
TEST-MRI-BRAIN-CONTRAST	MRI brain with contrast	Standard	imaging	—	desired (aggressive)
TEST-PET-CT	FDG PET/CT (whole body)	Standard	imaging	—	desired (aggressive)

Red flags — PRO / CONTRA aggressive

PRO-AGGRESSIVE

Triggers that push toward the aggressive track

BRAF V600E mutation in mCRC: ~8-10% prevalence, poor prognosis (median OS halved vs BRAF-WT on standard chemo). Cetuximab/panitumumab ineffective. Encorafenib + cetuximab (BEACON CRC) is preferred 2L+; some 1L data favor FOLFOXIRI + bev intensification in MSS BRAF-mutant. RF-CRC-BRAF-V600E-POOR-PROGNOSIS
Frailty/age profile precluding doublet-intensive or triplet chemo: ECOG ≥3, OR (age ≥80 + Charlson ≥3), OR composite (age ≥75 + albumin <3.0 + ≥2 comorbidities). Triggers de-escalation toward 5-FU/LV mono, capecitabine mono, or best supportive care. RF-CRC-FRAILTY-AGE
MSI-high / dMMR mCRC — treatment-defining biomarker. KEYNOTE-177 established pembrolizumab 1L over FOLFOX+bev (PFS 16.5 vs 8.2 mo). This RF intensifies toward the immunotherapy track and overrides the default RAS/BRAF-driven chemo algorithm. RF-CRC-MSI-H-ACTIONABILITY
Liver-limited oligometastatic colorectal cancer (CRLM, colorectal liver metastases) — a distinct subset of stage IV CRC where intensified treatment with hepatic resection (or ablation) added to systemic chemo is potentially curative. Definition (per NCCN Colon v3.2025 + ESMO CRC 2024 + EORTC 40983 / Nordlinger 2008 trial framework): ≤5 liver metastatic lesions, all R0-resectable on multidisciplinary review, no extrahepatic disease, ECOG 0-1 fitness, controllable primary tumour. Triggers MDT (medical onc + hepatobiliary surgery + radiation onc + radiology) consideration of perioperative FOLFOX (or FOLFOXIRI in selected patients) + hepatic metastasectomy. Distinct from gastroesophageal OMEC-1 oligomet (RF-OLIGOMET-DEFINITION) — CRC oligomet uses ≤5 liver lesions (not ≤3 distant), restricts to liver only (extrahepatic excluded), and HER2-positive does NOT disqualify (anti-HER2 second-line track separate from periop intensification decision). RF-CRC-OLIGOMET-LIVER-DEFINITION

CONTRA-AGGRESSIVE

Hard contraindications to escalation

Pembrolizumab (and other PD-1/PD-L1 inhibitors) augment T-cell responses; in patients with active autoimmunity or post-transplant immunosuppression, this can precipitate severe organ-specific flares (colitis, hepatitis, pneumonitis, transplant rejection) that may be fatal or require transplant loss. CI-PEMBROLIZUMAB-AUTOIMMUNE

What NOT to do

Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity

Standard plan (IND-CRC-METASTATIC-1L-RAS-WT-LEFT)

Do NOT use cetuximab/panitumumab in RAS-mutant CRC — bypassed signaling, no benefit
Do NOT use cetuximab in BRAF V600E mutant — confirmed no benefit (BEACON CRC)
Do NOT use cetuximab in right-sided RAS-WT — bevacizumab preferred per CALGB-80405
Do NOT skip rash prophylaxis — strongly correlates with response and impacts QoL

Aggressive plan (IND-CRC-OLIGOMET-LIVER-LIMITED)

Do NOT proceed without MDT review (medical onc + hepatobiliary surgery + radiation onc + radiology) — resectability assessment is the gate
Do NOT offer hepatic metastasectomy without ≤5 R0-resectable liver-limited lesions + adequate future liver remnant on imaging review
Do NOT include extrahepatic disease (lung, peritoneal, distant LN, brain) — these are explicit exclusions and route to standard 1L metastatic CRC management
Do NOT continue bevacizumab perioperatively — hold ≥6 weeks before hepatectomy due to wound-healing / hepatic-regeneration risk; resume post-recovery if indicated
Do NOT initiate during ongoing GI bleed / obstruction / perforation — emergency management first (RF-CRC-EMERGENCY-OBSTRUCTION-PERFORATION)
Do NOT default to non-MDT single-surgeon decision — refer to a hepatobiliary surgeon at an appropriate-volume centre

Aggressive plan (IND-CRC-METASTATIC-1L-MSI-H-PEMBRO)

Do NOT start FOLFOX/FOLFIRI ± bev/cetux in MSI-H mCRC 1L — substantial PFS loss vs ICI
Do NOT continue pembrolizumab through Grade 3+ immune-related AE without specialist consultation
Do NOT start pembrolizumab without prior MSI/dMMR confirmation by validated assay

Aggressive plan (IND-CRC-METASTATIC-1L-FOLFOXIRI-BEV)

Do NOT use in ECOG PS ≥ 2 — toxicity unacceptable; use doublet (FOLFOX+bev or FOLFIRI+bev)
Do NOT use in MSI-H/dMMR patients — pembrolizumab 1L is preferred (KEYNOTE-177)
Do NOT use without G-CSF prophylaxis — neutropenia rate ~50%
Do NOT omit irinotecan pre-medication (atropine — cholinergic prevention)
Do NOT add anti-EGFR (cetuximab/panitumumab) — triplet + anti-EGFR vs triplet + bev not superior per MACBETH/VOLFI; use one or the other
Do NOT continue past disease progression — switch promptly to 2L

Aggressive plan (IND-CRC-METASTATIC-1L-FOLFOX-BEV)

Do NOT initiate within 28 days of major surgery (perforation / dehiscence risk)
Do NOT continue bevacizumab through uncontrolled HTN >160/100
Do NOT use in patients with high-risk varices / active hemoptysis

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Induction · FOLFOX + Cetuximab

14-day cycles × Until progression / unacceptable toxicity

Aggressive plan

Induction · FOLFOX (mFOLFOX6)

14-day cycles × 12 cycles (6 mo) for adjuvant stage III; until progression / unacceptable toxicity for metastatic; 4 cycles (8 wk) periop trials

Aggressive plan

Induction · Pembrolizumab monotherapy (MSI-H mCRC 1L)

21-day cycles × Until progression / unacceptable toxicity / max 35 cycles per KEYNOTE-177

Aggressive plan

Induction · FOLFOXIRI + Bevacizumab

14-day cycles × Until progression / unacceptable toxicity; consider de-escalation after 4-6 months

Aggressive plan

Induction · FOLFOX + Bevacizumab

14-day cycles × Until progression / unacceptable toxicity (mCRC 1L)

MDT brief

Discussion questions (2, 1 blocking)

OQ-LDH-CURRENT
What is the current LDH? Marker of tumor burden and transformation.
LDH is part of the prognostic indices of indolent lymphomas.
→ hematologist
BLOCKING OQ-BIOMARKER-RAS-MUTATION
What is the status of RAS mutation status (KRAS / NRAS exons 2-4) (BIO-RAS-MUTATION)? It is required by track(s): IND-CRC-METASTATIC-1L-RAS-WT-LEFT. Expected value: RAS-WT.
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ molecular_geneticist

MDT talk tree (3 steps)

#	Owner	Topic	Action
1	molecular_geneticist	Biomarker status BLOCKING	What is the status of RAS mutation status (KRAS / NRAS exons 2-4) (BIO-RAS-MUTATION)? It is required by track(s): IND-CRC-METASTATIC-1L-RAS-WT-LEFT. Expected value: RAS-WT.
2	hematologist	Staging / disease burden	What is the current LDH? Marker of tumor burden and transformation.
3	clinical_pharmacist	Specialist review	Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.

Skills (recommended) — for consideration (2)

Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.
Molecular geneticist / molecular oncologist recommended
Indication references an actionable genomic biomarker — mutation / target / actionability interpretation needed.
Owns: OQ-BIOMARKER-RAS-MUTATION

Data quality

Incomplete for default-track review. Default-track review is incomplete until required biomarker gaps are resolved.

Biomarker coverage: 1/2 known (50%), 1 missing, 1 default-track gaps
Unevaluated RedFlags: RF-ACTIVE-AUTOIMMUNE-DISEASE-ICI-RISK, RF-CRC-EMERGENCY-OBSTRUCTION-PERFORATION, RF-CRC-FRAILTY-AGE, RF-CRC-HER2-AMP-ACTIONABLE, RF-CRC-INFECTION-SCREENING, RF-CRC-OLIGOMET-LIVER-DEFINITION, RF-CRC-RAS-MUTANT, RF-CRC-TRANSFORMATION-PROGRESSION

Missing biomarker	Label	MDT owner	Default track	Required by	Next action
`BIO-RAS-MUTATION`	RAS mutation status (KRAS / NRAS exons 2-4)	molecular_geneticist	yes	IND-CRC-METASTATIC-1L-RAS-WT-LEFT	Verify result, method, specimen, and report date before sign-off. Expected/constraint: RAS-WT

Technical MDT skill metadata (2/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Cellular therapy specialist (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Clinical pharmacist	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Hematologist / oncohematologist	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Infectious disease / hepatology	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Medical oncologist (solid-tumor chemotherapist)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Molecular geneticist / molecular oncologist	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Palliative care	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Pathologist (general)	`pathologist`	v0.1.0	2026-04-25	pathology
Primary care / family physician	`primary_care`	v0.1.0	2026-04-25	primary_care
Psycho-oncologist	`psychologist`	v0.1.0	2026-04-25	psychosocial
Radiation oncologist	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Radiologist	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Social worker / case manager	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Surgical oncologist	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Transplant specialist (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-ESMO-COLON-2024: ESMO CRC Clinical Practice Guideline (2024)
SRC-ESMO-CRC-2024: ESMO colorectal cancer guideline (2024) (TODO: confirm citation) ()
SRC-KEYNOTE-177-ANDRE-2020: Pembrolizumab versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer (2020)
SRC-NCCN-COLON-2025: NCCN Colon / Rectal Cancer (v.4.2025)
SRC-TRIBE-LOUPAKIS-2014: FOLFOXIRI plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Treatment of Metastatic Colorectal Cancer (2014)
SRC-TRIBE2-CREMOLINI-2020: FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE2 study (2020)

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-05-12.

NCT	Title	Phase	Status	Sponsor	UA	Signals
NCT06149481	Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)	PHASE1 / PHASE2	RECRUITING	National Cancer Institute (NCI)	—	Surrogate endpoint only Single country
NCT05378919	Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer	PHASE2	RECRUITING	Lithuanian University of Health Sciences	—	Surrogate endpoint only Single country
NCT05328765	A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection	N/A	RECRUITING	Latin American Cooperative Oncology Group	—	Single country
NCT07213609	A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors	PHASE1 / PHASE2	RECRUITING	GlaxoSmithKline	—	Small N (<50) Surrogate endpoint only
NCT06074536	Impact of Training Patient-centered Approach on Shared Decision in Colorectal Cancer Screening	NA	RECRUITING	CNGE Conseil	—	Single country
NCT04812912	Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer	N/A	RECRUITING	Memorial Sloan Kettering Cancer Center	—	Single country
NCT06663319	A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers	PHASE1	RECRUITING	Janssen Research & Development, LLC	—	Phase 1 only
NCT05848609	Functional Status and Quality of Life in Older Patients Undergoing Robotic Surgery for Colorectal Cancer	NA	RECRUITING	Universitair Ziekenhuis Brussel	—	Single country
NCT06815406	Recurrence Rate After Endoscopic Resection of , Laterally Spreading Tumor Granular Type (LST-G) of the Colon and Rectum: Endoscopic Mucosal Resection vs. Endoscopic Submucosal Dissection	NA	RECRUITING	Azienda USL Reggio Emilia - IRCCS	—	Single country
NCT07071714	A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer	PHASE2	RECRUITING	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	—	Surrogate endpoint only Single country

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).

Option	UA registration	NSZU	Cost orientation	Access pathway
Standard plan FOLFOX + Cetuximab (REG-FOLFOX-CETUX)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Aggressive plan FOLFOX (mFOLFOX6) (REG-FOLFOX)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Aggressive plan Pembrolizumab monotherapy (MSI-H mCRC 1L) (REG-PEMBROLIZUMAB-MSI-MONO)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Aggressive plan FOLFOXIRI + Bevacizumab (REG-FOLFOXIRI-BEV)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Aggressive plan FOLFOX + Bevacizumab (REG-FOLFOX-BEV)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Trial · NCT06149481 Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05378919 Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05328765 A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07213609 A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06074536 Impact of Training Patient-centered Approach on Shared Decision in Colorectal Cancer Screening No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04812912 Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06663319 A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05848609 Functional Status and Quality of Life in Older Patients Undergoing Robotic Surgery for Colorectal Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06815406 Recurrence Rate After Endoscopic Resection of , Laterally Spreading Tumor Granular Type (LST-G) of the Colon and Rectum: Endoscopic Mucosal Resection vs. Endoscopic Submucosal Dissection No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07071714 A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-05-12.

plan_id: PLAN-CRC-MET-RAS-WT-LEFT-1L-001-V1 | version: 1 | generated: 2026-05-12T18:41:26.881274+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.